Neumora Therapeutics, Inc. (NMRA)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 9.22 |
| Open | 9.22 |
| Bid | 9.23 x 100 |
| Ask | 9.27 x 200 |
| Day's range | 9.21 - 9.66 |
| 52-week range | 8.82 - 21.00 |
| Volume | |
| Avg. volume | 602,591 |
| Market cap | 1.475B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.63 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 25.25 |
GlobeNewswireNeumora Therapeutics to Participate in Upcoming Conferences in May
WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will participate in two investor conferences in May: BofA Securities Healthcare Conference 2024: Members of management will participate in a fireside chat on Tuesday, May 14, 2024, at 1:00 PM ET (10:00 AM PT) in Las Vegas, NV.2024
Simply Wall St.We're Hopeful That Neumora Therapeutics (NASDAQ:NMRA) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
ZacksBiotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.
© 2024 Yahoo. All rights reserved.